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Chemical synthesis of 4’-thio and 4’-sulfinyl
pyrimidine nucleoside analogues†
Mieke Guinan,a,b Ningwu Huang,c Chris S. Hawes, a Marcelo A. Lima, b,d
Mark Smithc and Gavin J. Miller *a,d
Analogues of the canonical nucleosides required for nucleic acid synthesis have a longstanding presence
and proven capability within antiviral and anticancer research. 4’-Thionucleosides, that incorporate bioi-
sosteric replacement of furanose oxygen with sulfur, represent an important chemotype within this field.
Established herein is synthetic capability towards a common 4-thioribose building block that enables
access to thio-ribo and thio-arabino pyrimidine nucleosides, alongside their 4’-sulfinyl derivatives. In
addition, this building block methodology is templated to deliver 4’-thio and 4’-sulfinyl analogues of the
established anticancer drug gemcitabine. Cytotoxic capability of these new analogues is evaluated against
human pancreatic cancer and human primary glioblastoma cell lines, with observed activities ranging
from low μM to >200 μM; explanation for this reduced activity, compared to established nucleoside ana-
logues, is yet unclear. Access to these chemotypes, with thiohemiaminal linkages, will enable a wider
exploration of purine and triphosphate analogues and the application of such materials for potential resis-
tance towards relevant hydrolytic enzymes within nucleic acid biochemistries.
1. Introduction
A significant proportion of current chemotherapeutic treat-
ments for cancer involve the use of anti-metabolites, particu-
larly modified nucleoside analogues that possess a capability
to mimic native purine or pyrimidine nucleosides, which can
disrupt metabolic and regulatory pathways.1 Notwithstanding
this significant medicinal capability, therapeutic intervention
using nucleoside analogues is often limited by poor cellular
uptake, low conversion to the active triphosphate metabolite,
rapid degradation or clearance and development of resistance
profiles in certain cell types.2 Consequently, research activity
in this field continues to develop syntheses for next gener-
ations of nucleoside analogues that can overcome these limit-
ations and provide new therapeutic options.3–5
Within this context, 4′-thionucleosides, where the furanose
ring oxygen is substituted with sulfur, have received attention
from several academic and industrial groups since a first dis-
closure of 4′-thioadenosine in the early 1960s;6,7 Fig. 1 high-
lights some key achievements in this area. Bioisosteric replace-
ment of furanose oxygen with larger sulfur seeks to explore the
biological effect imparted through changes to furanose ring
conformation and the hydrolytic stability of a thiohemiaminal
glycosidic linkage.
Insertion of a sulfur atom to access thiofuranose com-
ponents generally start from available chiral pool materials
and the use of thiourea to convert 4,5-epoxides to 4,5-
thiiranes,8,9 alongside sodium sulfide-mediated formation of
2,5-bicyclic systems are notable examples of key intermediates
developed to enable this.10–12 Open chain systems have also
been used,13 for example, effecting double displacement of a
1,4-bismesylate with Na2S to access 1-deoxy thiofuranoses,
14
and both C1 aldehyde and thioacetal oxidation levels have deli-
vered access to anomeric thioglycosides.15,16 Two main
approaches have been adopted to install appropriate nucleo-
bases; firstly thioglycosylation of a silylated nucleobase,8,17
and, secondly a Pummerer-type reaction of the sulfoxide to
condense with a corresponding nucleobase.16,18 Hypervalent
iodine reagents have also been used to effect a similar
transformation.19
As part of a program exploring chemical synthesis
approaches to next generation nucleoside scaffolds, we were
interested in accessing appropriate 4′-thionucleosides and
templating this bioisosteric replacement onto established che-
motypes, a tactic recently implemented by Liotta and col-
leagues for 2′-C-methyl-4′-thionucleosides.20 Herein we report
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our synthesis of 4′-thio and 4′-sulfinyl nucleosides; we targeted
an open-chain C1-oxime to enable sulfur inclusion using dis-
placement of an appropriate 4-position leaving group, with
concomitant ring closure onto a C1 aldehyde. This was
intended to provide a benchmark in then accessing related 2′-
deoxy-2′,2′-gem-difluoro and D-arabino structures which, along-
side recent examples 2′-deoxy-2′-fluoro and L-3′-deoxy-3′,3′-
difluoro systems,13,21,22 provides capability to more broadly
study 4′-thionucleoside chemotypes and their structure activity
relationships. These aims are highlighted in Fig. 2.
2. Results and discussion
2.1. Synthesis of a 4-thioribose building block and extension
to a 2-deoxy-2,2-difluoro-4-thioribose analogue
In order to access our intended series of thionucleoside deriva-
tives, a scalable and reliable method for the synthesis of
4-thio-D-ribofuranose 1 was required (Scheme 1). Starting from
commercially available 2, the anomeric acetate was hydrolysed
using H2O/BF3·OEt2 in 91% yield on 100 g scale. The resultant
hemi-acetal was used crude and converted to the corres-
ponding oxime 3 via treatment with O-methoxyhydroxylamine
hydrochloride and Et3N. This material was isolated as a
mixture of oxime isomers (3/1 ratio) in 90% yield, again on
multigram scale. Manipulation of the C4 position in 3 to facili-
tate conversion to the final thiofuranose, with retention of the
C4-ribo-configuration, was explored next. Direct halogenation
and inversion of stereochemistry at C4 using CBr4 or Br2 with
PPh3 proved unsuccessful, returning only starting material.
Instead, the C4-OH in 3 was converted to an arylsulfonyl
leaving group. Initially here we targeted a 4-nitrobenzenesulfo-
nate, but persistent low yields (maximum obtained = 31%) and
a requirement for chromatography led us to explore other
options. An earlier report of a less common 2,3,5-tricholoro-
benzensulfonate proved fruitful,23 delivering 4 in 72% yield.
Purification of 4 was achieved using trituration from Et2O,
enabling easy isolation as a white solid. This material could be
prepared in multigram amounts in 56% overall yield for three
steps from 2 and required no column chromatography.
Nucleophilic displacement of the 4-sulfonyl group within 4
was explored using LiBr in a Finkelstein-type reaction. The use
of DMI/THF as the solvent at 60 °C for 16 h resulted in a
mixture of C4 diastereoisomers (3/1, S/R, see ESI Fig. S4†), pre-
sumably forming via a second nucleophilic displacement of
bromide 5 to give the unwanted the C4-R epimer. Similar
issues surrounding unwanted C4 epimerisation were encoun-
tered by Codée and co-workers during their synthesis of 4-thio-
furanosides.14 Reducing the reaction time to 2 h in the same
solvent system improved the diastereomeric outcome (10/1, S/
R), however, this was accompanied by incomplete consump-
tion of 4. Switching solvent to 2-butanone and heating at 80 °C
for 18 h delivered diastereomerically pure C4-bromide 5 in
89% yield. 13C NMR analysis of 5 confirmed an upfield shift of
Fig. 1 Historical and current examples of thionucleosides (blue sulphur) with additional ring substituent modifications (red).
Fig. 2 (a) Strategy to access 4-thioribose derivative 1 as a key intermediate for 4’-thionucleoside synthesis and (b) potential therefrom to template
to established nucleoside analogue classes (blue box).
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C4 to δC 47.8 ppm, from δC 79.6 ppm. Treatment of bromide 5
with glyoxylic acid at 70 °C effected hydrolysis of the oxime to
the corresponding aldehyde in 92% yield, which was used
immediately for conversion to the desired 4-thiofuranose 6.
This proceeded via reaction with NaSH, effecting SN2 displace-
ment of the C4 bromide followed by ring closure onto the C1-
aldehyde, obtaining 6 as a mixture of anomers in 76% yield.
Crude 6 was treated with Ac2O in pyridine with catalytic DMAP
to obtain the acetylated product 1 as a mixture of anomers (4/
1, β/α). Simple trituration from MeOH isolated the β-anomer of
1 exclusively in a satisfactory 50% yield from 5, with analytical
data confirming those reported previously for D-ribo thiofura-
noses.9 The development of this synthetic route to 1 required
no column chromatography and was completed starting from
100 g of 2, delivering 1 in an overall yield of 25% for the seven
steps and in 25 g quantity.
The chemistry developed in Scheme 1 was next mapped
onto a 2-deoxy-2,2-gem-difluoro ribose system to access 4′-thio-
gemcitabine and analogues thereof (Scheme 2). Commercially
available lactone 7 was manipulated in six steps to deliver
2-deoxy-2,2-difluoro-1-(4-thio-D-ribofuranose) 10. Lactone 7 was
first reduced using Li(OtBu)3AlH to the hemiacetal in 95%
crude yield and then converted directly to oxime 8 via reaction
with O-methoxyhydroxylamine and Et3N in the presence of pyr-
idinium p-toluenesulfonate. Interestingly, no reaction to
convert the intermediate hemi-acetal was observed in the
absence of the pyridinium salt. Oxime 8 then underwent suc-
cessive derivatisation at C4, first to the sulfonate ester and
then nucleophilic substitution to yield bromide 9. Finally,
oxime hydrolysis was followed by incorporation of sulfur at C4
to restore the D-ribo configuration and subsequent cyclisation
to thiohemiacetal 10. This enabled access to multigram quan-
tities of 10 in 6 steps and 56% overall yield from the commer-
cial starting material.
The anomeric hydroxyl group in 10 was next converted to
either mesylate 11 or acetate 12 as appropriate leaving groups
to explore glycosylation of nucleobases. Treatment of 10 with
MsCl and Et3N (Scheme 2) afforded 11 in 79% yield as a 1/4,
α/β mixture. The β-anomer was isolated by crystallisation from
hot Et2O and the resultant solid recrystallised by diffusion
using CH2Cl2/hexanes to afford pure β-11. A sample of β-11
was analysed by X-ray crystallography and confirmed the
Scheme 1 (a) BF3·Et2O, H2O, MeCN, rt, 91%; (b) H2N-OMe·HCl, Et3N, MeOH, rt, 90%; (c) 2,4,5-Trichlorobenzenesulfonyl chloride,
N-methylimidazole, MeCN, rt, 72%; (d) LiBr, butanone, 80 °C, 89%. (e) (i) Glyoxylic acid, MeCN, 70 °C, 92%; (ii) NaSH·H2O, H2O, DMF, 0 °C, 76%; (f )
DMAP, Ac2O, rt, 72% (β-only); Ar = 2,4,5-trichlorophenyl.
Scheme 2 (a) Li(OtBu)3AlH, THF, 0 °C, 95%; (b) H2N-OMe·HCl, Et3N, MeCN, H2O, pyridinium p-toluenesulfonate, rt, 90% (c) 2,4,5-
Trichlorobenzenesulfonyl chloride, N-methylimidazole, MeCN, rt 75% (d) LiBr, butanone, 80 °C. (e) (i) Glyoxylic acid, MeCN, 70 °C (ii) NaSH·H2O,
H2O, DMF, 0 °C, 97% over 3 steps (f ) MsCl, Et3N, CH2Cl2, rt, 79% (53% for β-anomer only) (g) Ac2O, Et3N, CH2Cl2, rt, 88%.
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double stereochemical inversion at C4, which retained a D-ribo
configuration (Fig. 3). The anomeric mesylate and C5 were
observed above the plane of the thiopentose ring, consistent with
1-β-D-ribo stereochemistry, with the ring adopting a C3-endo con-
formation in the solid state. Anomeric acetate 12 was accessed in
88% yield as a 3/2 mixture of anomers that, in our hands, proved
inseparable by crystallisation or column chromatography.
2.2. Synthesis of 4′-thioribo- and 4′-thioarabino nucleosides
With access to multigram scale quantities of 1, a series of 4′-
thioribo and 4′-thioarabino pyrimidines were targeted. A
pathway to access these was proposed from 4′-thiouridine 14
(Scheme 3). Comparative literature for the synthesis of 2′,3′,5′-
tri-O-benzoyl protected uridine involved refluxing the reactants
for 3 h in acetonitrile, following silyation of the nucleobase.24
However, reaction under these conditions for 1 produced low
yields of 13 (20–30%). By conducting the reaction just below
the boiling point of MeCN, at 75 °C, the yield improved signifi-
cantly, to 74%. The β-anomer of 13 formed preferentially (1H
NMR of crude 13 indicated a 10/1, β/α ratio, [3JH1–H2 = 6.8 Hz
for β-13]) and the reaction was scalable to 10 g.25
Global deprotection of 13 was completed using 7 M NH3 in
MeOH to obtain 4′-thiouridine 14 in 96% yield. This material was
next converted to its cytosine form, first by treatment of 14 with
POCl3 and then 1,2,4-triazole to furnish the heterocyclic inter-
mediate, before a final treatment with NH3 in MeOH concomi-
tantly substituted the triazole and removed the benzoyl protecting
groups to give 4′-thiocytidine 15 in 77% yield over two steps.
4′-thiouridine 14 was also converted to its C2′ epimer 18 via
an intramolecular cyclisation of the C4-carbonyl, displacing a
C2′-carbonate leaving group. This inverted the C2′ stereo-
chemistry to give β-1′,2′-syn-bicycle 17 in 92% yield, with 13C
NMR confirming a chemical shift change of δC 152.3 ppm to
δC 175.4 ppm for C2′ in 17. Subsequent ring opening of 17 was
achieved by stirring with KOH in EtOH/H2O, to give C2′-
arabino configured 18 in almost quantitative yield. The
observed 1H NMR coupling constant between H2′ and H3′ for
18 (3JH2′–H3′ = 9.1 Hz) was significantly different than that
observed for 14 (3JH2′–H3′ = 3.7 Hz), supporting inversion of
stereochemistry at C2′. 4′-thioarabinouridine 18 was also con-
verted to its cytosine form using the method previously estab-
lished for 15, delivering 4′-thioarabinocytidine 19 in 52% yield
over three steps from 18. Earlier efforts to directly convert 15 to
19 via a β-1′,2′-syn-intermediate bi-cycle were unsuccessful;
multiple reaction products were observed and this conversion
was abandoned. Finally, the corresponding sulfoxides of 15
and 19 were prepared via treatment with 1.5 equivalents of
m-CPBA, to afford novel 16 and 20 in 90% and 78% yields
Fig. 3 X-ray crystal structure of β-11 with numbering scheme for core
atoms. ADPs are rendered at 50% probability level and ring disorder on
the C5 phenyl ester substituent is omitted for clarity. Atom colouring
scheme: black = carbon, red = oxygen, green = fluorine, yellow = sulfur,
pink = hydrogen.
Scheme 3 (a) (i) Uracil, HMDS, reflux (ii) TMSOTf, MeCN, 75 °C, 74% (b) 7 M NH3 in MeOH, MeOH, 40 °C, 96% (c) POCl3, 1,2,4-triazole, Et3N, MeCN,
rt (d) NH4OH, 1,4-dioxane, rt, then 7 M NH3 in MeOH, MeOH, 40 °C, 77%, 2 steps from 13 (e) m-CPBA, H2O, MeCN, 0 °C, 90%, 1/1 d.r. at S (f )
(PhO)2CO, NaHCO3, DMF, 100 °C, 98% (g) KOH, EtOH, H2O, rt, 90% (h) Ac2O, DMAP, pyridine, rt, 82% (i) POCl3, 1,2,4-triazole, Et3N, MeCN, rt ( j) 7 M
NH3 in MeOH, MeOH, 120 °C, 70%, 2 steps from 18 (k) m-CPBA, H2O, MeCN, 0 °C, 78%, 2.5/1 d.r. at S.
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respectively. 13C NMR analysis confirmed a significant down-
field shift of C1′ and C4′ from δC 65.1 and 51.7 ppm in 16 to δC
73.1 and 65.7 ppm in 20 respectively. Attempted separation of
the S-diastereoisomers by crystallisation and reverse phase pre-
parative HPLC were unsuccessful.
2.3. Synthesis of 4′-thio and 4′-sulfinylgemcitabine
In order to access 2-deoxy-2,2-gem-difluorothionucleosides, we
returned to anomeric acetate 12 and mesylate 11 to investigate
nucleobase attachment. Prior reports suggested use of an
anomeric mixture of 11 delivered the corresponding nucleo-
sides as a 1/1, α/β mixture, regardless of the anomeric ratio of
the starting mesyl glycoside.10,26 In order to target 4′-thiogem-
citabine, silylated N4-benozyl cytosine was first glycosylated
with donor 11, using TMSOTf as activator. These conditions
were unsuccessful (no product was isolated) and SnCl4 was
selected instead. Under these conditions the desired nucleo-
side was isolated, but in <10% yield. Accordingly, we switched
glycosyl donor to anomeric acetate 12 and were pleased to
observe an improved yield for glycosylation of silylated N4-
benozyl cytosine, delivering 21 in 28% yield, with 25% of 12
recovered. Expectedly, no diastereocontrol was observed for
this glycosylation; 21 was isolated as a 1.1/1 anomeric mixture,
requiring subsequent separation either using fractional pre-
cipitation or preparative HPLC. Following protecting group
removal, 22-α was confirmed through selective 1D NOESY,
where though-space dipolar interactions between H1 and H3
were observed (Scheme 4 and ESI Fig. S5†). Anomer 22-β was
then oxidised at sulfur to afford the 4′-sulfinyl derivative of 4′-
thiogemcitabine. Oxidation was confirmed through a signifi-
cant downfield shift of C1′ and C4′ from δC 59.7 and 46.3 ppm
respectively in 22-β to δC 84.6 and 72.8 ppm respectively in 23.
2.4. Biological Evaluation
Nucleoside analogues 15, 16, 19, 20, 22-β and 23 were evalu-
ated in cytotoxicity assays against human pancreatic cancer
(PANC-1) and human primary glioblastoma (U87-MG) cells
and their CC50 values compared to commercial arabinocyti-
dine (Ara-C) and gemcitabine (Table 1). Only analogue 19 dis-
played measurable cytotoxicity, with a CC50 value of 0.59 μM in
U87-MG cells and 12 μM in PANC-1 cells (entry 3, Table 1); all
other analogues had CC50 values >200 μM. The data for 19
were not immediately comparable to Ara-C or gemcitabine, as
both displayed superior CC50 values in the cell lines evaluated
(entries 1 and 2, Table 1). These results suggest that a thio
arabino chemotype may impart some degree of cytotoxicity,
but that replacement of furanose oxygen with sufinyl is not
tolerated.
3. Conclusions
We have developed a scalable and column chromatography
free synthesis of a protected 4-thioribose intermediate. This
synthetic methodology has also been adapted for a multigram
preparation of 2-deoxy-2-gem-difluoro 4-thioribose analogues.
These building blocks enable entry to a range of pyrimidine-
based 4′-thionucleoside analogues, including first examples of
4′-sulfinyl derivatives of ribocytidine, Ara-C and gemcitabine.
From the compounds synthesised, 4′-thioarabinocytidine
was shown to have moderate cytotoxicity towards U87-MG
cells, but generally all the thionucleosides evaluated showed
little cytotoxicity. This is most likely due to the compounds
being poor substrates for nucleotide-forming kinases,27 essen-
tial for converting to the active triphosphate. Alternatively, the
Table 1 Cytotoxicity data for 19, Ara-C and Gemcitabine in U87-MG
and PANC-1 cells
Entry Compound
CC50 (µM) CC50 (µM)
U87-MG PANC-1
1 Ara-C 0.19 0.43
2 Gemcitabine 0.01 0.21
3 19 0.59 12.0
Scheme 4 (a) N4-Benzoyl cytosine, HMDS, pyridine, SnCl4, DCE, reflux, 28% (25% returned 12), 1/1, α/β, then fractional precipitation, 10% for 21-α,
6% for 21-β. (b) From 21-α/β, NH3, MeOH, 40 °C, 96% crude, then preparative HPLC, 44% for 22-α, 34% for 22-β; From 21-β, NH3, MeOH, 63% (c)
m-CPBA, H2O, MeCN, 15%, 4/1 d.r. at S.
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thionucleoside triphosphates might not be substrates for
human polymerases. Further work to access monophosphate
prodrug forms of these analogues is currently underway and
will be reported in due course.
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